Carregant...
A farewell to didanosine: harm reduction and cost savings by eliminating use of didanosine
Didanosine (ddI) is a nucleoside reverse transcriptase inhibitor associated with adverse events and public health concerns which have diminished its place in clinical practice, particularly in resource-rich settings. While international guidelines do not contain ddI-containing regimens in preferred...
Guardat en:
| Publicat a: | Int J STD AIDS |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4677683/ https://ncbi.nlm.nih.gov/pubmed/25281538 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0956462414554433 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|